RxDoctor Payments Data

Annika Evans

Women's Health · Dallas, TXNPI 1407912009

Payments from drug & device makers

$781in general payments, 2019–2025

Across 38 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$422
  • Urovant Sciences Inc$92
  • Axonics, Inc.$77
  • Sumitomo Pharma America, Inc.$68
  • AbbVie$50
  • 180 Medical, Inc.$21
  • plus $51 from 4 others

What the payments were for

  • Food & beverage$60177%
  • Education$18023%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc19$422
Urovant Sciences Inc4$92
Axonics, Inc.4$77
Sumitomo Pharma America, Inc.3$68
AbbVie(2 entities)3$50
180 Medical, Inc.1$21
Allegis Pharmaceuticals, LLC1$14
Hollister Incorporated1$13
Valencia Technologies Corporation1$12
Therapeuticsmd, Inc.1$12

How this compares

$781 in reported general payments places this provider in the 70th percentile of 609 women's health providers in Texas.

See all women's health providers in Texas

Medicare billing

Part B allowed, 2024
$80,033
Medicare patients
419
Services billed
1,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron110$95,291
GemtesaVibegron80$74,499
Estradiol172$11,994
Trospium Chloride175$10,274
Mirabegron ErMirabegron12$6,698
Methenamine Hippurate69$6,167
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst64$1,343
Clobetasol Propionate21$625
Cephalexin40$508
Triamcinolone Acetonide39$364
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav57$316
Nystatin20$281
Doxycycline Monohydrate12$184
Amitriptyline Hcl12$162
Fluconazole18$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$422$95,291110 claims
Sumitomo Pharma America, Inc.Gemtesa$68$74,49980 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 609 women's health providers in Texas.

Other women's health in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →